Improved Antitumor Efficiency of N 4 -Tetradecyloxycarbonyl Gemcitabine-Loaded Liposomes for Pancreatic Cancer Chemotherapy.
Autor: | Wang D; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China., Wang X; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China., Li Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China., Wang X; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China., Wang X; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China., Su J; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China., Wang A; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China., Lv K; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China., Liu M; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China., Xia G; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China. |
---|---|
Jazyk: | angličtina |
Zdroj: | International journal of nanomedicine [Int J Nanomedicine] 2024 Dec 11; Vol. 19, pp. 13391-13410. Date of Electronic Publication: 2024 Dec 11 (Print Publication: 2024). |
DOI: | 10.2147/IJN.S485861 |
Abstrakt: | Background: Gemcitabine (Gem) is one of the first-line chemotherapy drugs for pancreatic cancer treatment. However, its short half-life in plasma and adverse effects limited its broader application. Methods: A novel Gem derivative ( N 4 -tetradecyloxycarbonyl gemcitabine, tcGem) was synthesized and encapsulated into liposomes (LipotcGem) to overcome the above shortcomings. Results: LipotcGem has been successfully formulated, with the average size of 115 nm, zeta potential values of -36 mV, encapsulation efficiency of up to 98%, and drug loading capacity of 8.1%. Compared to Gem, LipotcGem improved in vitro antitumor activity significantly, as evidenced by the lower IC Conclusion: LipotcGem significantly increased the anti-tumor efficiency and decreased the toxicity for chemotherapy of pancreatic cancer. Competing Interests: Dr Dan Wang reports a patent Anti-tumor lipid composition licensed to CN112245391. Miss Yan Li reports a patent Anti-tumor lipid composition issued to CN202011145564.6. Prof. Dr. Apeng Wang reports a patent Anti-tumor compound licensed to CN202011145601.3. Professor Mingliang Liu reports a patent Anti-tumor compound licensed to CN202011145601.3, a patent Anti-tumor lipid composition issued to CN202011145564.6. Professor Guimin Xia reports a patent Anti-tumor compound licensed to CN202011145601.3, a patent Anti-tumor compound composition issued to CN202011145564.6. The authors report no other conflicts of interest in this work. (© 2024 Wang et al.) |
Databáze: | MEDLINE |
Externí odkaz: |